Rama Reddy, MD
Endocrinology · Belleville, NJNPI 1386724672
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 463 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,737 and has fallen 88.5% since, to $199 in 2025.
Across 463 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$946
- Lilly USA, LLC$924
- Boehringer Ingelheim$716
- Novo Nordisk$609
- Mannkind Corporation$503
- plus $3K from 26 others
What the payments were for
- Food & beverage$7,666100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 58 | $1,028 |
| Amgen | 73 | $946 |
| Lilly USA, LLC | 66 | $924 |
| Boehringer Ingelheim | 28 | $716 |
| Novo Nordisk | 38 | $609 |
| Mannkind Corporation | 43 | $503 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $473 |
| Johnson & Johnson | 6 | $409 |
| Abbott | 18 | $370 |
| Sanofi-aventis U.S. LLC | 17 | $239 |
| Novartis | 13 | $225 |
| Insulet Corporation | 7 | $203 |
| Merck | 9 | $119 |
| AbbVie | 7 | $114 |
| Kowa Pharmaceuticals America, Inc. | 8 | $114 |
| Zealand Pharma US, Inc. | 5 | $105 |
| Radius Health, Inc. | 5 | $72 |
| Dexcom, Inc. | 4 | $62 |
| Endo Pharmaceuticals Inc. | 4 | $56 |
| Amneal Pharmaceuticals LLC | 4 | $55 |
| Medtronic | 3 | $54 |
| Cequr Corporation | 2 | $51 |
| BD | 3 | $44 |
| IBSA Pharma Inc. | 3 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Recordati_rare_diseases_inc. | 2 | $31 |
| Valeritas, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Pfizer | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| Lifescan, Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 149 | $237,886 |
| OzempicSemaglutide | 156 | $229,035 |
| JardianceEmpagliflozin | 185 | $225,131 |
| Tresiba Flextouch U-100Insulin Degludec | 179 | $152,830 |
| TradjentaLinagliptin | 136 | $115,518 |
| FarxigaDapagliflozin Propanediol | 91 | $109,728 |
| ProliaDenosumab | 61 | $99,908 |
| TrulicityDulaglutide | 62 | $98,684 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 25 | $57,911 |
| RybelsusSemaglutide | 24 | $52,181 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $48,051 |
| Repatha SureclickEvolocumab | 63 | $42,936 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $39,153 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $36,646 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 27 | $36,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $924 | $345,968247 claims |
| Boehringer IngelheimJardiance, Tradjenta | $716 | $340,649321 claims |
| Novo NordiskOzempic, Rybelsus | $609 | $281,216180 claims |
| AmgenProlia, Evenity (2 Syringes) | $946 | $157,81986 claims |
| AstraZenecaFarxiga | $1,028 | $109,72891 claims |
| MerckJanumet, Januvia, Janumet Xr | $119 | $73,32562 claims |
| AbbVieSynthroid | $114 | $7,24197 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $5,730577 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Belleville
- Oscar OrtizToms River$176K
- Merab JosephFair Lawn$99K
- Caryn BorgerFlorham Park$68K
- Brian FertigPiscataway$4K
- Samar BurshehVentnor City$4K
- Monika AkulaNeptune$4K
- Saleh KhaddashClifton$2K
- Muqdad HasanGlen Ridge$900
- Andrew ParzialeMorristown$0
- Alexa YuenMorristown$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.